Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ANGPTL4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANGPTL4 Full-Length / N-Terminal / C-Terminal Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ANGPTL4 Products |
| Gene Delivery | ANGPTL4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ANGPTL4 Products |
| Benchmark Ab | Anti-ANGPTL4 Benchmark Antibody Recombinant positive control for assay calibration. |
View ANGPTL4 Products |
| Validator | ANGPTL4 siRNA Set For knockdown verification. |
View ANGPTL4 Products |
| Related Target A | LPL (Lipoprotein Lipase) Primary downstream target inhibited by ANGPTL4 in lipid metabolism. |
View LPL Products |
| Related Target B | ANGPTL3 Synergistic metabolic regulator; dual-targeting bypasses resistance. |
View ANGPTL3 Products |
| Related Target C | ANGPTL8 Forms functional complexes with ANGPTL3/4 to regulate LPL activity. |
View ANGPTL8 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Proteolytic Cleavage Differentiation | Sequence Verified N-terminal (CCD) and C-terminal (FLD) domain specific proteins available with >95% purity. |
| Cross-species Translation (Human to Mouse) | Human, Mouse, and Cynomolgus ortholog proteins available with strict endotoxin control for preclinical safety evaluation. |
| Lack of Assayed Controls | Clinical Benchmark Antibodies included for precise SPR/ELISA calibration. |
| Target Specificity (Subfamily Off-Target) | High purity homologous panel (ANGPTL3, ANGPTL8) available for strict counter-screening and cross-reactivity profiling. |
Live ANGPTL4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Connect market trends to assay needs. The race for ANGPTL4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to nucleic acid therapies (siRNA/ASO) and domain-specific biologics. Because ANGPTL4 plays a pleiotropic role—its N-terminal fragment regulates lipid metabolism through LPL inhibition, while its C-terminal fragment drives tumor angiogenesis and metastasis—precision targeting is critical. As first-generation lipid-lowering therapies reach the clinic, the next wave of R&D is targeting tissue-specific delivery (e.g., GalNAc-conjugated ASOs) to mitigate lymphatic toxicities, exploring domain-specific inhibition and tissue-selective delivery to uncouple metabolic benefits from angiogenic risks, and exploring bispecific formats targeting the ANGPTL3/4/8 axis to achieve profound synergistic effects in severe metabolic syndrome and oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Regeneron, Novartis | Hypertriglyceridemia, Solid Tumors | Domain Specificity Assay (Need high-purity N-term vs C-term ECD-Fc) |
| ASO / siRNA | Ionis, Arrowhead | Metabolic Syndrome, Dyslipidemia | Knockdown Validation (Need Validator siRNA & Benchmark Abs) |
| Bispecific (ANGPTL3/4) | Various Biotechs | Severe Hyperlipidemia | Selectivity Assay (Need Homolog panel proteins: ANGPTL3, ANGPTL8) |
| Small Molecule | Academic Consortia | Metastatic Cancers | Inhibitor Screening (Need Native Glycosylated HEK293 Proteins) |